Abstract: Provided herein are compositions and methods to that target microbial proteases to ameliorate the intestinal barrier dysfunction and restore mucosal integrity. They are useful to treat and prevent diseases and disorders caused by pathogenic bacteria in the gastrointestinal system of a subject.

Abstract: A method for predicting an outcome of treating an ulcerative colitis patient with vedolizumab may include applying a predictive model to determine a response indicator indicative of the outcome of treating the ulcerative colitis patient with vedolizumab. The predictive model may be based on a plurality of predictive factors including a duration of disease, an exposure to tumor necrosis factor antagonist therapy, a baseline endoscopy corresponding to a disease severity, and/or a concentration of albumin. The response indicator may include a probability of the ulcerative colitis patient responding to vedolizumab, achieving a clinical remission and/or an endoscopic remission of ulcerative colitis with vedolizumab, requiring surgical intervention, and/or encountering an infection when treated with vedolizumab. A treatment plan including a dose schedule for administering vedolizumab to the ulcerative colitis patient may be determined based on the response indicator.